22nd Century Group Crecimiento futuro
Future controles de criterios 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for 22nd Century Group.
Información clave
n/a
Tasa de crecimiento de los beneficios
n/a
Tasa de crecimiento del BPA
Crecimiento de los beneficios de Tobacco | 19.1% |
Tasa de crecimiento de los ingresos | n/a |
Rentabilidad financiera futura | n/a |
Cobertura de analistas | None |
Última actualización | n/a |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Market Participants Recognise 22nd Century Group, Inc.'s (NASDAQ:XXII) Revenues Pushing Shares 1,233% Higher
Apr 02Time To Worry? Analysts Just Downgraded Their 22nd Century Group, Inc. (NASDAQ:XXII) Outlook
Aug 20With 22nd Century Group, Inc. (NASDAQ:XXII) It Looks Like You'll Get What You Pay For
Jun 14Does 22nd Century Group (NASDAQ:XXII) Have A Healthy Balance Sheet?
Jan 1322nd Century adds Creager as distribution partner for its VLN cigarettes in Colorado
Oct 03En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como 22nd Century Group no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.
Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.
Previsiones de crecimiento de beneficios e ingresos
Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
---|---|---|---|---|---|
6/30/2024 | 19 | -51 | -27 | -25 | N/A |
3/31/2024 | 19 | -63 | -43 | -40 | N/A |
12/31/2023 | 22 | -65 | -61 | -55 | N/A |
9/30/2023 | 27 | -101 | -75 | -69 | N/A |
6/30/2023 | 27 | -41 | -75 | -69 | N/A |
3/31/2023 | 30 | -38 | -67 | -61 | N/A |
12/31/2022 | 28 | -37 | -56 | -52 | N/A |
9/30/2022 | 49 | -47 | -41 | -37 | N/A |
6/30/2022 | 39 | -44 | -32 | -30 | N/A |
3/31/2022 | 30 | -36 | -28 | -27 | N/A |
12/31/2021 | 31 | -33 | -24 | -23 | N/A |
9/30/2021 | 23 | -25 | -22 | -21 | N/A |
6/30/2021 | 25 | -20 | -17 | -16 | N/A |
3/31/2021 | 28 | -21 | -15 | -15 | N/A |
12/31/2020 | 28 | -20 | -16 | -16 | N/A |
9/30/2020 | 28 | -20 | -16 | -16 | N/A |
6/30/2020 | 27 | -26 | -18 | -17 | N/A |
3/31/2020 | 27 | -29 | -16 | -15 | N/A |
12/31/2019 | 26 | -27 | -16 | -15 | N/A |
9/30/2019 | 26 | -29 | -18 | -17 | N/A |
6/30/2019 | 26 | -13 | -20 | -18 | N/A |
3/31/2019 | 27 | -11 | -20 | -19 | N/A |
12/31/2018 | 26 | -8 | -19 | -18 | N/A |
9/30/2018 | 25 | -3 | -16 | -15 | N/A |
6/30/2018 | 24 | -12 | -15 | -13 | N/A |
3/31/2018 | 20 | -9 | N/A | -13 | N/A |
12/31/2017 | 17 | -13 | N/A | -12 | N/A |
9/30/2017 | 14 | -12 | N/A | -12 | N/A |
6/30/2017 | 13 | -11 | N/A | -11 | N/A |
3/31/2017 | 11 | -11 | N/A | -10 | N/A |
12/31/2016 | 12 | -12 | N/A | -10 | N/A |
9/30/2016 | 12 | -12 | N/A | -10 | N/A |
6/30/2016 | 11 | -12 | N/A | -10 | N/A |
3/31/2016 | 11 | -10 | N/A | -8 | N/A |
12/31/2015 | 9 | -11 | N/A | -7 | N/A |
9/30/2015 | 6 | -14 | N/A | -8 | N/A |
6/30/2015 | 3 | -14 | N/A | -8 | N/A |
3/31/2015 | 1 | -14 | N/A | -8 | N/A |
12/31/2014 | 1 | -16 | N/A | -7 | N/A |
9/30/2014 | 8 | -18 | N/A | 2 | N/A |
6/30/2014 | 8 | -30 | N/A | 3 | N/A |
3/31/2014 | 8 | -29 | N/A | 4 | N/A |
12/31/2013 | 7 | -26 | N/A | 4 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Insufficient data to determine if XXII's forecast earnings growth is above the savings rate (2.5%).
Beneficios vs. Mercado: Insufficient data to determine if XXII's earnings are forecast to grow faster than the US market
Beneficios de alto crecimiento: Insufficient data to determine if XXII's earnings are expected to grow significantly over the next 3 years.
Ingresos vs. Mercado: Insufficient data to determine if XXII's revenue is forecast to grow faster than the US market.
Ingresos de alto crecimiento: Insufficient data to determine if XXII's revenue is forecast to grow faster than 20% per year.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Insufficient data to determine if XXII's Return on Equity is forecast to be high in 3 years time